Company Overview of Nano Bridging Molecules S.A.
Nano Bridging Molecules S.A. (NBM) focuses on research, development, manufacturing, and marketing of SurfLink, a suite of medical implant surface modifications for rendering medical implants biocompatible with the human body. The company’s SurfLink product is a chemical compound made up of multi-phosphonated molecules that naturally fuse implants to surrounding human tissue. NBM, formerly known as Suriasis S.A., was incorporated in 2002 and is based in Gland, Switzerland.
Route de Cité-Ouest 2
Founded in 2002
41 22 354 00 54
41 22 354 00 55
Key Executives for Nano Bridging Molecules S.A.
Similar Private Companies By Industry
|AB2 Bio Ltd.||Europe|
|ADC Products Switzerland SARL||Europe|
|ADC Therapeutics SA||Europe|
|AlloCyte Pharmaceuticals AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Nano Bridging Molecules S.A., please visit www.nbmolecules.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.